SCHEDULE: Iradimed Insider Ownership Update: Susi Family Holdings

Roger E. Susi and associated family trusts report a combined 34.8% beneficial ownership stake in Iradimed Corporation.

Summary

• Roger E. Susi and related entities (Roger E. Susi Revocable Trust, Matthew Susi 2008 Dynasty Trust, Phillip Susi 2008 Dynasty Trust, and J. Richard Susi) filed an amendment to their Schedule 13G.
• The reporting persons collectively beneficially own 4,450,450 shares of Iradimed Corporation common stock.
• This aggregate holding represents approximately 34.8% of the company's 12,783,035 outstanding shares as of April 30, 2026.
• The filing clarifies the distribution of voting and dispositive power among the trusts and individual family members.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing that confirms existing ownership structures without indicating new strategic shifts or financial performance changes.

Positives

• Significant alignment of interest between the founder/insiders and shareholders, with over one-third of the company held by the Susi family.

Negatives

• High concentration of ownership may limit the influence of minority shareholders in corporate governance matters.

Risks

• Concentrated ownership by the Susi family could potentially lead to conflicts of interest or influence strategic decisions that may not align with all public shareholders.
• Changes in the trusts' structure or the potential for future divestment by these major holders could create volatility in the share price.

Future Outlook

The filing does not provide operational guidance or future business outlook, as it is a regulatory disclosure regarding beneficial ownership.

Industry Context

StockSavvy.ai notes that high insider ownership is common in mid-cap medical device companies, often signaling long-term commitment from founders, though it necessitates close monitoring of governance practices.

Comparison to Industry Standards

• The 34.8% insider ownership is significantly higher than the average for publicly traded medical device companies of similar market capitalization, where institutional ownership typically dominates.
• The structure of using dynasty trusts for estate planning is a standard practice for high-net-worth founders in the sector.

Corporate Governance

Related Party Transactions

• The filing details the relationship between Roger E. Susi (settlor) and the various trusts (RT, MT, PT) and J. Richard Susi (trustee).

Stakeholder Impact

• Shareholders should be aware of the high concentration of voting power held by the Susi family, which may influence board composition and major corporate decisions.

Next Steps

• Continued monitoring of future Form 4 filings for any changes in the Susi family's holdings.

Key Dates

Keywords

Iradimed, IRMD, Schedule 13G, Insider Ownership, Beneficial Ownership, Susi Family, Corporate Governance